This study was presented in phase 2, in a healthy population between 50 and 80 years of age, and it showed the use of Bentracimab reverts the antiplatelet effect of ticagrelor.
The study included 205 adults mean age 61, 49% women, previously treated with aspirin and ticagrelor for 48 hrs. who were randomized 3:1 to get bentracimab or placebo, with platelet function measured afterwards.
Primary end point was minimum percent platelet inhibition within 4 hours and showed a significant advantage in favor of bentracimab (P < 0.0001). There were no differences in adverse events between groups.
Conclusion
The use of Bentracimab is effective and safe to revert the antiplatelet effect of ticagrelor. Further study is needed to assess clinical efficacy.
Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org .
Reference: Bhatt DL. Bentracimab immediately and significantly reverses the antiplatelet effects of ticagrelor in older people. Presented at: ACC 2022. April 2, 2022. Washington, DC.
Subscribe to our weekly newsletter
Get the latest scientific articles on interventional cardiology
